TScan Therapeutics, Inc.
TCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$127,499 | -$89,218 | -$66,221 | -$48,625 |
| Dep. & Amort. | $4,108 | $5,361 | $5,137 | $3,328 |
| Deferred Tax | $0 | $0 | $0 | -$9,162 |
| Stock-Based Comp. | $9,549 | $5,208 | $4,551 | $2,516 |
| Change in WC | $5,054 | $17,606 | -$10,230 | -$5,896 |
| Other Non-Cash | -$2,034 | -$315 | $260 | $9,162 |
| Operating Cash Flow | -$110,822 | -$61,358 | -$66,503 | -$48,677 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$3,825 | -$3,146 | -$4,225 | -$9,941 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$241,445 | -$77,613 | $0 | $0 |
| Inv. Sales/Matur. | $192,657 | $20,000 | $0 | $0 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$52,613 | -$60,759 | -$4,225 | -$9,941 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $15,313 | $0 | $29,354 | $0 |
| Stock Issued | $33,131 | $42,414 | $193 | $89,647 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $160,321 | $93,029 | -$191 | $100,021 |
| Financing Cash Flow | $208,765 | $135,443 | $29,356 | $189,668 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $45,330 | $13,326 | -$41,372 | $131,050 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $138,390 | $125,064 | $166,436 | $35,386 |
| End Cash | $183,720 | $138,390 | $125,064 | $166,436 |
| Free Cash Flow | -$114,647 | -$64,504 | -$70,728 | -$58,618 |